February 4, 2010

Eurand Announces Conference Call on Fourth Quarter and Full-Year 2009 Financial Results

AMSTERDAM, THE NETHERLANDS, Feb 04, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, will host a conference call on Thursday, March 4, 2010 at 8:30 a.m. ET to discuss its fourth quarter and full-year 2009 financial results. The conference call will be hosted by Gearoid Faherty, Chairman and Chief Executive Officer, and Mario Crovetto, Chief Financial Officer.

The conference call schedule is as follows:

7:00 a.m. ET: Release of fourth quarter and full-year 2009 financial
              results
8:20 a.m. ET: Dial in to participate in the conference call:
              -- U.S. Participants dial 1-877-407-9039
              -- International Participants dial +1-201-689-8470
8:30 a.m. ET: Conference call begins
Call Replay: A replay of the call will be available from 11:30 a.m. ET on
March 4, 2010 until April 4, 2010.  The Account Number is: 3055; Conference
ID Number: 343839.
              -- U.S. Participants dial 1-877-660-6853
              -- International Participants dial +1-201-612-7415

Webcast: A live webcast of the call also will be available from the Investor Relations section of the corporate web site at www.eurand.com. Following the live webcast, the archived version of the call will be available at the same URL until April 4, 2010.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles and taste-masking orally disintegrating tablet (ODT) formulations.

Eurand is a global company with facilities in the U.S. and Europe. For more information, visit Eurand's website at www.eurand.com.

Contacts:

Bill Newbould
Vice President, Investor Relations
Eurand N.V.
+1 267-759-9335
Email Contact

Nick Laudico/Sara Pellegrino
The Ruth Group
+1 646-536-7030/7002
Email Contact
Email Contact


SOURCE: Eurand N.V.

http://www2.marketwire.com/mw/emailprcntct?id=1FD2CB9E20A22A4B
http://www2.marketwire.com/mw/emailprcntct?id=6DCB1DBA7C257586
http://www2.marketwire.com/mw/emailprcntct?id=C0D9B20E6C4579A7

Copyright 2010 Marketwire, Inc., All rights reserved.

News Provided by COMTEX


Close window | Back to top


Copyright 2010 Eurand Pharmaceuticals